• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ALLHAT: Thiazide diuretics as first-line antihypertensive therapy [Classics Series]

byAndrew Cheung, MD MBA
September 22, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. There were no significant differences in the rates of fatal coronary heart disease or nonfatal myocardial infarction when comparing thiazide diuretics with ACE-Is or CCBs in hypertension management.

2. Thiazide diuretics are the cheapest option amongst common first-line antihypertensives.

Original Date of Publication: December 18, 2002

Study Rundown: Hypertension is considered a major risk factor for cardiovascular disease and blood pressure control is an international priority. Some studies have estimated that 26.4% of the global population suffered from hypertension in 2000, and this number is expected to increase to 29.2% in 2025, affecting an estimated 1.56 billion people. While antihypertensive medication therapy has been shown to reduce the risk of adverse outcomes in hypertensive patients, there are many antihypertensive agents available and questions remained regarding the best choice for initial therapy. The earliest studies demonstrated benefits associated with using thiazides and beta-blockers (BB), though many new agents were subsequently introduced into practice, including angiotensin-converting enzyme inhibitors (ACE-Is) and calcium channel blockers (CCBs).

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, controlled trial published in 2002. The main trial focused specifically on high-risk patients – it sought to determine whether there were significant differences in rates of cardiovascular events when using different first-line antihypertensive agents, such as ACE-Is (i.e., lisinopril), CCBs (i.e., amlodipine), alpha-blockers (i.e., doxazosin), and thiazides (i.e., chlorthalidone). The alpha-blocker arm was terminated early, as chlorthalidone was found to be superior to doxazosin. In summary, there were no significant differences in the rates of fatal coronary heart disease (CHD) or nonfatal myocardial infarction when comparing chlorthalidone with amlodipine (RR 0.98; 95%CI 0.90-1.07) or lisinopril (RR 0.99; 95%CI 0.91-1.08) for hypertension management. Because thiazide diuretics are cheaper than other options, it was recommended that they be considered first-line therapy for hypertension based on the findings of this study.

Click to read the study in JAMA

In-Depth [randomized, controlled study]: The study involved 33,357 participants and had a mean follow-up of 4.9 years. Patients were eligible for the study if they were ≥55 years of age and had stage 1 or 2 hypertension with ≥1 additional risk factor (i.e., previous myocardial infarction, stroke, left ventricular hypertrophy, type 2 diabetes, current cigarette smoking, low high-density lipoprotein). Exclusion criteria were history of heart failure and/or left ventricular ejection fraction <35%. The primary outcome was fatal CHD or nonfatal myocardial infarction, while the secondary outcomes were all-cause mortality, fatal/nonfatal stroke, combined CHD, and combined cardiovascular disease. Chlorthalidone was found to be superior to doxazosin, and the alpha-blocker arm was terminated early.

RELATED REPORTS

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

Dietary insoluble fiber intake may be associated with lower risk of hypertension

In the comparison between amlodipine and chlorthalidone, there were no significant differences in the primary (RR 0.98; 95%CI 0.90-1.07) or secondary outcomes. Amlodipine, however, was associated with a significantly higher risk of heart failure, particularly hospitalized/fatal heart failure (p<0.001). The comparison between lisinopril and chlorthalidone again demonstrated no significant differences in the primary (RR 0.99; 95%CI 0.91-1.08) or secondary outcomes; but, lisinopril use was associated with significantly elevated risk of stroke, combined cardiovascular disease, heart failure, hospitalized/treated angina, and coronary revascularization. Moreover, participants in the lisinopril group had significantly higher follow-up systolic blood pressure.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: allhatallhat trialhypertension
Previous Post

Light drinking during pregnancy may be safe

Next Post

Algorithm improves pediatric chronic cough outcomes

RelatedReports

UTI associated with increased risk of preeclampsia
Cardiology

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

March 6, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

March 6, 2023
Provision of medically-tailored meals linked with lower admissions and medical spending
Cardiology

Dietary insoluble fiber intake may be associated with lower risk of hypertension

February 22, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Telephone health coaching intervention ineffective for improving outcomes for hypertension

February 11, 2023
Next Post
Algorithm improves pediatric chronic cough outcomes

Algorithm improves pediatric chronic cough outcomes

X-ray after foreign body removal by esophagoscopy is not cost effective

X-ray after foreign body removal by esophagoscopy is not cost effective

Parents’ feeding control practices related to child’s weight and gender

Parents’ feeding control practices related to child’s weight and gender

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Patients with early pregnancy loss less likely to receive active management in the emergency department
  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options